JP2018537480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537480A5 JP2018537480A5 JP2018530763A JP2018530763A JP2018537480A5 JP 2018537480 A5 JP2018537480 A5 JP 2018537480A5 JP 2018530763 A JP2018530763 A JP 2018530763A JP 2018530763 A JP2018530763 A JP 2018530763A JP 2018537480 A5 JP2018537480 A5 JP 2018537480A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- independently
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 176
- -1 halo-C1-6 alkoxy Chemical group 0.000 claims 93
- 125000001424 substituent group Chemical group 0.000 claims 77
- 125000005842 heteroatom Chemical group 0.000 claims 59
- 229910052760 oxygen Inorganic materials 0.000 claims 57
- 229910052717 sulfur Chemical group 0.000 claims 57
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 54
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 43
- 229910052757 nitrogen Inorganic materials 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 38
- 229910052736 halogen Inorganic materials 0.000 claims 37
- 150000002367 halogens Chemical class 0.000 claims 35
- 125000002757 morpholinyl group Chemical group 0.000 claims 27
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 23
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 21
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 17
- 125000003386 piperidinyl group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000004434 sulfur atom Chemical group 0.000 claims 15
- GGTBELZDHKHESR-UHFFFAOYSA-N 2-cycloheptyloxazepane Chemical compound C1CCCCCC1N1OCCCCC1 GGTBELZDHKHESR-UHFFFAOYSA-N 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000002393 azetidinyl group Chemical group 0.000 claims 12
- 125000000842 isoxazolyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000004193 piperazinyl group Chemical group 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 9
- 239000001301 oxygen Substances 0.000 claims 9
- 125000005551 pyridylene group Chemical group 0.000 claims 9
- 239000011593 sulfur Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000005549 heteroarylene group Chemical group 0.000 claims 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 8
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 125000000815 N-oxide group Chemical group 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 208000007613 Shoulder Pain Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004889 cervical nerve Anatomy 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000019000 fluorine Nutrition 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CC(C(C)C1*CCC1)C1CCCC1 Chemical compound CC(C(C)C1*CCC1)C1CCCC1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510900083.4 | 2015-12-08 | ||
| CN201510900083.4A CN106854207B (zh) | 2015-12-08 | 2015-12-08 | 呔嗪类衍生物、其制备方法、药物组合物和用途 |
| PCT/CN2016/108975 WO2017097217A1 (zh) | 2015-12-08 | 2016-12-08 | 呔嗪类衍生物、其制备方法、药物组合物和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537480A JP2018537480A (ja) | 2018-12-20 |
| JP2018537480A5 true JP2018537480A5 (enExample) | 2019-02-28 |
| JP6669868B2 JP6669868B2 (ja) | 2020-03-18 |
Family
ID=59013670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530763A Active JP6669868B2 (ja) | 2015-12-08 | 2016-12-08 | フタラジン誘導体、その製造方法、医薬組成物および使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11220503B2 (enExample) |
| EP (1) | EP3388433B1 (enExample) |
| JP (1) | JP6669868B2 (enExample) |
| CN (1) | CN106854207B (enExample) |
| WO (1) | WO2017097217A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3766882B1 (en) * | 2018-03-12 | 2023-08-23 | Shanghai Simr Biotechnology Co., Ltd. | Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof |
| CN112979655A (zh) | 2019-12-16 | 2021-06-18 | 上海赛默罗生物科技有限公司 | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| US20240059691A1 (en) * | 2020-12-01 | 2024-02-22 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| CN112441901B (zh) * | 2020-12-15 | 2023-08-29 | 山东泰和科技股份有限公司 | 一种乙酸酐的合成方法 |
| CN116008443B (zh) * | 2023-03-28 | 2023-06-30 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂类药物中有关物质的检测方法 |
| CN119019425A (zh) * | 2023-05-26 | 2024-11-26 | 武汉人福创新药物研发中心有限公司 | 一种作为α5-GABAA受体调节剂的杂环化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9112504D0 (en) | 1991-06-11 | 1991-07-31 | Merck Sharp & Dohme | Cell line |
| DE69320985T2 (de) | 1992-12-10 | 1999-05-12 | Merck Sharp & Dohme | Stabil transfizierte zelllinien welche gaba-a rezeptoren exprimieren |
| AU732455C (en) | 1997-05-08 | 2002-09-05 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo{3,4-a}phthalazine derivatives as gaba alpha 5 ligands |
| GB9715977D0 (en) | 1997-07-29 | 1997-10-01 | Merck Sharp & Dohme | Therapeutic agents |
| US6297235B1 (en) * | 1997-08-28 | 2001-10-02 | Merck Sharp & Dohme Ltd. | Triazolopyridazine derivatives for treating anxiety and enhancing cognition |
| IL149550A0 (en) * | 1999-11-12 | 2002-11-10 | Neurogen Corp | Bicyclic and tricyclic heteroaromatic compounds |
| GB0028583D0 (en) * | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US20050043982A1 (en) * | 2003-08-22 | 2005-02-24 | Nguyen Vinh Dinh | Contextual workflow modeling |
| JP2007509150A (ja) * | 2003-10-21 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | 神経障害性疼痛の治療において有用なトリアゾロ−ピリダジン化合物および、この誘導体 |
| US10206921B2 (en) | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
-
2015
- 2015-12-08 CN CN201510900083.4A patent/CN106854207B/zh active Active
-
2016
- 2016-12-08 WO PCT/CN2016/108975 patent/WO2017097217A1/zh not_active Ceased
- 2016-12-08 EP EP16872406.0A patent/EP3388433B1/en active Active
- 2016-12-08 US US16/060,256 patent/US11220503B2/en active Active
- 2016-12-08 JP JP2018530763A patent/JP6669868B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537480A5 (enExample) | ||
| JP2019532078A5 (enExample) | ||
| JP2013530236A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| HRP20210526T1 (hr) | Oksisteroli i postupci za njihovu uporabu | |
| JP2019515952A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2015509535A5 (enExample) | ||
| RU2019115113A (ru) | Оксистеролы и способы их применения | |
| JP2017519781A5 (enExample) | ||
| JP2015523406A5 (enExample) | ||
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP2016510758A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| NZ630875A (en) | Heterocyclic compounds and uses thereof | |
| CA3026602C (en) | Pyrrolopyrimidine crystal for preparing jak inhibitor | |
| JP2016540742A5 (enExample) | ||
| JP2016519165A5 (enExample) | ||
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| JP2020527175A5 (enExample) | ||
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| JP2017524733A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2015516427A5 (enExample) |